Norepynefryn | Norepinephrine agetan ampoules 2 mg / ml 8 ml, 10 pcs.

Latin name

Noradrenaline Aguettant

Release form

Concentrate for preparing a solution for intravenous injection

Packing

10 pcs

Pharmacological action

Norepinephrine agetan - adrenomimetic.

Pharmacodynamics

l- and 2-adrenergic receptor agonist. It weakly excites 1 - and practically does not affect ​​2-adrenergic receptors. It has a powerful vasoconstrictor effect, leads to an increase in blood pressure.

Pharmacokinetics

Not absorbed in the digestive tract. With iv administration, it rapidly reaches Cmax in plasma (within 2–3 min).

Metabolized in the liver, kidneys and blood plasma with the participation of MAO and catechol-O-methyltransferase (COMT) to almost inactive metabolites that are excreted through the kidneys.

Indications

Acute hypotension accompanying cardiovascular collapse and shock (to restore and maintain blood pressure - iv perfusion).

Contraindications

severe hypersensitivity to the drug

arterial hypotension due to hypovolemia. An exception in these cases is the need to administer the drug to maintain blood flow in the coronary arteries of the heart and brain arteries before the end of therapy aimed at restoring bcc

mesenteric and peripheral vascular thrombosis due to the risk of aggravating ischemia and enlarging the

infarction zone conducting fluorotan and cyclopropane general anesthesia due to the risk of ventricular tachycardia and fibrillation)

severe hypoxia and hypercapnia.

Precautions: severe left ventricular failure, acute heart failure, recent myocardial infarction

simultaneous administration of MAO inhibitors of imipramine and tryptiline series (due to the risk of developing a pronounced and prolonged increase in blood pressure)

development of symptoms of cardiac arrhythmia (in this case, a dose reduction is necessary). With polymorphic extrasystole or the development of volleys of extrasystoles, the dose of the drug should be significantly reduced or treatment canceled.

Use in pregnancy and lactation

Pregnancy is not a limitation for the use of Norepinephrine Agetan. At the time of treatment, breast-feeding should be stopped (there is no experience with the drug in nursing women).

Composition

1 ml. contains:

Active ingredient: norepinephrine tartrate monohydrate (in terms of norepinephrine tartrate) 2 mg / ml

Excipients: sodium chloride sodium hydroxide or hydrochloric acid (pH = 3.0ִ.5) water for injection.

Dosage and administration

Intravenously, preferably in the vein of the elbow.

Concentrate should be diluted in 5% glucose solution or 0.9% sodium chloride solution. Do not mix with other drugs. With the introduction of Noradrenaline Agetan, it is necessary to constantly monitor blood pressure and heart rate.

After diluting the concentrate, the solution should be used within 12 hours.

The individual dose is determined depending on the clinical condition of the patient. An initial dose and rate of administration of 0.1 to 0.3? G / kg / min of norepinephrine tartrate is recommended. The maximum dose and rate of administration used in the treatment of septic and hemorrhagic shock can reach 3–5? G / kg / min.

Side effects

With the administration of Norepinephrine Agetan, the following symptoms may occur: ischemic disorders up to necrosis, caused by vasoconstriction and tissue hypoxia, as well as caused by extravasation of

arrhythmia

reflex bradycardia

anxiety

shortness of breath

tremor

transient headache

chest pain, swallowing pain and swelling mild pain In especially sensitive patients, an increase in blood pressure may be accompanied by headache, photophobia, stitching chest pain, pallor of the skin, increased sweating and vomiting.

With prolonged use, a dose adjustment is necessary to avoid recurrent hypotension during drug withdrawal.

Drug interaction

The main undesirable effects when combined with some groups of drugs are pharmacodynamic.

Serious ventricular arrhythmias (increased cardiac irritability) may occur when combined with inhaled anesthetic drugs.

When combined with serotonergic and adrenergic antidepressants, and also derivatives of imipramine and amitriptyline, paroxysmal hypertension may develop with a risk of cardiac arrhythmia due to an adrenergic blocking effect on the sympathetic nervous system.

Combination of Norepinephrine Agetan with selective and non-selective MAO inhibitors, linezolid, is contraindicated. at the same time, a synergistic increase in the pressor action of norepinephrine occurs, which requires careful medical monitoring.

Overdose

Symptoms: skin vascular spasm, collapse, anuria, marked elevation of blood pressure may occur.

Treatment: In the event of overdose, the dose of the drug should be reduced.

Storage Conditions

In a dry, dark place at a temperature not exceeding 30 РC.

shelf life

2 years

Deystvuyushtee substance

Norэpinefrin

Terms of dispatch from

pharmacies Prescription of

dosage form

infusion solution

Possible product names

NORADRENALIN AGETAN 0, 002 / ML 8ML N10AMP END

Noradrenaline Agetan 2mg / ml conc. d / prg. solution for iv input. 8ml Amp. X10 B (R)

Norepinephrine agetan ampoules 2 mg / ml 8 ml, 10 pcs.

NORADRENALINE AGHETAN END. Prigot. R-RA I / O INTRODUCTION. 2MG / ML AMP. 8ML No. 10

NORADRENALIN AGETAN CONC. Prigot. R-RA I / O INTRODUCTION. 2MG / ML AMP. 8ML No. 10 (09.13)

Laboratory Agetan, France